Manipal Health Enterprises Limited has officially opened its Initial Public Offering (IPO) for public subscription today, July 29, 2026. The public issue will remain open until July 31, 2026, while the company's equity shares are expected to be listed on both the NSE and BSE on August 5, 2026, subject to the completion of the allotment process and regulatory approvals. With an issue size of ₹9,275 crore, the IPO is among the largest public offerings in India's healthcare sector and one of the biggest IPOs of 2026.
The company has fixed the IPO price band at ₹560 to ₹590 per equity share, with a minimum lot size of 25 shares. At the upper price band, retail investors are required to make a minimum investment of ₹14,750. The public issue comprises a fresh issue worth ₹8,000 crore and an Offer for Sale worth ₹1,275 crore by existing shareholders.
Ahead of the public subscription, the IPO generated significant interest from institutional investors during the anchor book allocation. Strong participation from domestic mutual funds, insurance companies, sovereign funds, and foreign institutional investors reflected confidence in the company's long-term growth prospects and leadership position in India's private healthcare industry.
Manipal Health Enterprises is one of India's largest private healthcare providers, operating a nationwide network of 49 multi-speciality hospitals with more than 13,000 operational beds. The company provides tertiary and quaternary healthcare services across specialties including cardiology, oncology, neurosciences, orthopaedics, nephrology, gastroenterology, organ transplantation, critical care, and emergency medicine.
Over the past few years, the hospital chain has expanded rapidly through acquisitions and organic growth. The integration of major healthcare networks, including Columbia Asia, Vikram Hospital, AMRI Hospitals, Medica Synergie, and Sahyadri Hospitals, has significantly strengthened its presence across North, South, East, and West India. This expansion has helped Manipal Health become one of the country's largest integrated hospital networks.
According to the company's offer documents, the majority of the fresh issue proceeds will be used for repayment and prepayment of borrowings of its subsidiary, reducing the group's debt burden and strengthening its balance sheet. A portion of the proceeds will also be utilised for acquiring the remaining minority stake in Sahyadri Hospitals Private Limited, while the balance will be allocated toward general corporate purposes.
In addition to reducing debt, the company has announced an ambitious expansion strategy. Management plans to invest approximately ₹4,000 crore over the next three to four years to add nearly 2,400–3,000 new hospital beds, further strengthening its footprint in key metropolitan and high-growth healthcare markets across India. The expansion is expected to increase treatment capacity while supporting future revenue growth.
India's healthcare sector continues to benefit from increasing health insurance penetration, rising disposable incomes, greater awareness of preventive healthcare, an ageing population, and growing demand for specialised medical services. These long-term structural trends are expected to support sustained growth for organised hospital operators with established clinical capabilities and nationwide networks.
One of Manipal Health's key strengths is its diversified revenue model. The company serves patients through self-pay, corporate healthcare programmes, government health schemes, insurance companies, and third-party administrators. This diversified payer mix helps reduce dependence on any single revenue source while supporting consistent occupancy and cash flow generation.
Financially, the company has reported strong operational performance driven by higher patient volumes, improving occupancy levels, increased average revenue per occupied bed (ARPOB), and growth in high-value speciality treatments. Continued focus on operational efficiency and expansion has strengthened investor confidence ahead of the IPO.
Market sentiment ahead of the issue has remained positive. Grey market activity indicates a premium of around ₹25 per share, suggesting favourable expectations before listing. However, the Grey Market Premium (GMP) is an unofficial market indicator and should not be considered a guarantee of listing gains. Investors should evaluate the company's financial performance, growth strategy, valuation, and long-term fundamentals before making investment decisions.
Despite its strong market position, investors should also consider certain business risks. The healthcare industry is capital intensive and requires continuous investment in infrastructure, medical technology, specialist doctors, and regulatory compliance. Profitability may also be influenced by changes in healthcare regulations, insurance reimbursement policies, operating costs, and competitive dynamics. Successfully integrating acquisitions and executing expansion projects will remain important for sustaining future growth.
With subscriptions now open, Manipal Health Enterprises has become one of the most closely watched IPOs of 2026. Backed by a leading hospital network, strong brand recognition, nationwide presence, planned capacity expansion, and a debt reduction strategy, the company is expected to remain in focus throughout the subscription period. Investors will closely monitor demand across retail, non-institutional, and institutional categories before the company's proposed listing on August 5, 2026.
